Case study: How 360 qualitative insights gave strategic direction into the development of an oncology biomarker

The solution
We conducted 104 qualitative face-to-face and telephone interviews with a range of different stakeholders; Oncologists, Surgeons, Radiologists and Pathologists in Canada, France, Germany, Italy, Japan, Spain, UK and US. 360°feedback on the process and the involvement of individual HCP types was gleaned using a highly explorative discussion around the processes and decision points involved. From this, decision trees were developed and opportunities and threats to testing were identified.

The outputs
We provided our client with conclusions and recommendations based on biopsy and tissue availability, testing logistics and reactions to our client’s new biomarker assay profile. From our analysis we successfully provided key insights regarding the market landscape of molecular diagnostic testing whilst further offering advice regarding next steps and opportunities for our client’s biomarker.